AMC stock bounces, in wake of credit upgrade; GameStop stock also rises

Referenced Symbols

Shares of AMC Entertainment Holdings Inc. AMC, -13.23% bounced 3.9% in premarket trading Friday, after falling 22.2% over the past two sessions. The stock, along with some other meme stocks, took a hit Thursday after GameStop Corp. GME, -27.16% disclosed that the Securities and Exchange Commission was looking into the "trading activity" in its stock and those of other companies. GameStop's stock rallied 6.1% ahead of Friday's open, after tumbling 27.2% on Thursday. Late in Thursday's session, AMC's credit rating was upgraded by two notches, to CCC+ from CCC-, by S&P Global Ratings, which said the movie theater operator's recent equity capital raises "makes it less likely that AMC will pursue a subpar debt exchange or other forms of debt restructuring in the near future." AMC said it raised $1.25 billion from equity in the second quarter, and S&P Global pegged the capital raises at roughly $1.8 billion this year. The credit rating agency said AMC's credit outlook is positive, which suggests potential for another upgrade. The CCC+ rating, which still suggests AMC's debt is "vulnerable for nonpayment," is still seven notches deep into speculative grade, or "junk" territory. The bounce in AMC's stock, and GameStop's, comes as futures ES00, +0.21% for the S&P 500 SPX, +0.47% edged up 0.1%.

Read Next

Read Next

Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

Shares of Orphazyme A/S undefined blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock undefined, which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite undefined gained 0.8% and the S&P 500 undefined rose 0.5%.

More On MarketWatch

About the Author